Apellis (NASDAQ: APLS) holder files Rule 144 to sell 2,618 shares

Rhea-AI Filing Summary

Apellis Pharmaceuticals has a shareholder planning to sell 2618 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of 58086.09, on or about 01/13/2026 on the NASDAQ exchange. The filing notes that 126525218 shares of the issuer’s stock are outstanding. The 2618 shares being sold were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation, indicating they are newly vested shares now eligible for resale under Rule 144.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2618	58086.09	126525218	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	Restricted Stock Vesting	Issuer			2618	01/12/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for APLS disclose?

The Form 144 discloses that a shareholder of Apellis Pharmaceuticals (APLS) intends to sell 2618 shares of common stock under Rule 144 through Fidelity Brokerage Services LLC.

How many Apellis (APLS) shares are planned to be sold and at what value?

The notice covers 2618 common shares of Apellis with an aggregate market value of 58086.09 as indicated in the filing.

When were the Apellis (APLS) shares acquired and how?

The 2618 shares to be sold were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation.

When is the planned sale date for the Apellis (APLS) shares?

The approximate date of sale listed is 01/13/2026, with the shares expected to be sold on the NASDAQ exchange.

How many Apellis (APLS) shares are outstanding according to this notice?

The filing reports that 126525218 common shares of Apellis are outstanding, providing context for the size of the planned Rule 144 sale.

Which broker is handling the planned Apellis (APLS) Rule 144 sale?

The Form 144 states that the planned sale of 2618 Apellis common shares will be executed through Fidelity Brokerage Services LLC in Smithfield, RI.